June 26, 2019
MSD K.K., the Japan arm of US Merck, rolled out on June 25 its broad-spectrum antibiotic injection Zerbaxa, containing novel cephalosporin ceftolozane and the β-lactamase inhibitor tazobactam, after a four month delay due to a stable supply issue. Zerbaxa is...read more